Anastrozole and Trastuzumab
About
Membership operator: AND
Therapies: 2
Therapies
Anastrozole (tx:ncit:C1607)
Trastuzumab (tx:ncit:C1647)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | ER positive, HER2-positive, PR positive | Invasive Breast Carcinoma | Anastrozole, Trastuzumab | |
| EMA (1) | ER positive, HER2-positive | Invasive Breast Carcinoma | Anastrozole, Trastuzumab | |
| EMA (1) | ER positive, ERBB2 amplification, PR positive | Invasive Breast Carcinoma | Anastrozole, Trastuzumab | |
| EMA (1) | ER positive, ERBB2 amplification | Invasive Breast Carcinoma | Anastrozole, Trastuzumab | |
| EMA (1) | ERBB2 amplification, PR positive | Invasive Breast Carcinoma | Anastrozole, Trastuzumab | |
| EMA (1) | HER2-positive, PR positive | Invasive Breast Carcinoma | Anastrozole, Trastuzumab |